Nectero Medical Closes $96M Series D Financing to Advance Endovascular Aneurysm Stabilization Treatment System

Компания Nectero Medical завершила раунд финансирования серии D на сумму 96 миллионов долларов, возглавляемый Norwest Venture Partners, при участии Boston Scientific, BioStar Capital, Cadence Healthcare Ventures, Aphelion Capital и других инвесторов, с целью ускорения проведения клинических испытаний фазы II/III (stAAAble) и подготовки заявки на регистрацию нового лекарственного препарата (NDA) в Управление по санитарному надзору за качеством пищевых продуктов и медикаментов США (FDA) для системы эндоваскулярной стабилизации аневризмы Nectero EAST®.

The Nectero EAST System, which was granted Breakthrough Therapy designation by the US FDA in November 2023, is an investigational, single-use, endovascular system that delivers pentagalloyl glucose (PGG) locally into the aneurysmal wall, where it binds to elastin and collagen to strengthen the aortic vessel wall and to potentially reduce further degradation. The procedure takes less than an hour and leaves no permanent implant behind. In January 2024, Nectero Medical initiated a Phase II/III clinical trial (stAAAble) to investigate the safety and efficacy of the Nectero EAST System in patients with infrarenal abdominal aortic aneurysms (AAAs) with a maximum diameter of 3.5 – 5.0 cm.

To view the source version, please click HERE.